Dandiss technology CO.,LTD is a fast-growing biopharmaceutical company that engages in the research, development and manufacturing of Active Pharmaceutical Ingredients and Intermediates with primary focus on the high-end API market and late-stage drug candidates. The Company has achieved revenue growth rate of over 100% annually since its establishment in 2001. It has been rewarded research grants by the Ministry of Science and Technology for innovative breakthroughs in a number of patented pharmaceutical intermediates.
       
       
       
       Headquartered in the Center for New Medicine Discovery and Research in Hangzhou , BrightGene is aggressively committed to the commercialization of the following leading products in its rapidly expanding pipeline:
       
       
       
       entecavir and intermediates 
       
       Posaconazole intermediates 
       
       Fondaparinux sodium intermediate 
       
       Lapatinib intermediates 
       
       pemetrexed disodium and intermediates 
       
       Aliskiren intermediates 
       
       In addition, our commitment extends to delivering excellent products and services for clients around the globe and partnering with companies and institutions whose strength will augment our own.